Advancing Hemophilia Gene Therapy with Optimized AAV3 Vectors
The scientific team members of aaVective have, over the past nearly four decades, advanced the potential and utility of AAV vectors. aaVective is uniquely positioned to overcome the technological challenges other gene therapy companies targeting hemophilia have encountered, and will continue to encounter. The aaVective team possesses novel insights into the basic biology of AAV vectors in general, and AAV3 vectors in particular, that hold the key to a permanent cure of hemophilia with a one-time treatment.
Why AAV3 Vectors?